DreaMed Diabetes is an Israeli startup (Tel Aviv) that develops AI-driven solutions for diabetes care and management. Its flagship product, the endo.digital platform, uses artificial intelligence to generate personalized recommendations for insulin treatment to help healthcare providers optimize care. The company was founded in 2014 by Prof. Moshe Philip, Eran Atlas, Prof. Revital Nimri, and Ido Muller. DreaMed has agreements and partnerships with organizations including Abbott and Yale New Haven Health. With the newly raised funds, the company plans to expand operations in the U.S., advance its platform, grow the team, scale efforts, and enhance its technology. The articles do not disclose revenue or user metrics. DreaMed Diabetes is a Petah Tikva, Israel-based developer of diabetes treatment and management solutions that use algorithms and decision-support tools to optimize intensive insulin therapy for people with Type 1 and Type 2 diabetes. Founded in 2014 and led by CEO Eran Atlas and CCO Steve Bubrick, the company builds products aimed at personalized insulin treatment. Its first product, GlucoSitter™, was developed for closed-loop insulin therapy and was licensed to Medtronic. The company’s latest product, Advisor™, is a decision-support technology platform that determines optimal patient-specific insulin treatment plans to achieve balanced glucose levels. Advisor uses event-driven machine learning and logic to process personalized parameters such as insulin delivery data, glucose readings, and meal data. DreaMed raised $3.3M and will use the funds for further development of Advisor. DreaMed Diabetes, founded in 2014 and based in Petah Tikva, Israel, develops diabetes treatment and management software centered on its MD-Logic Artificial Pancreas algorithm. Its flagship product, the CE‑approved GlucoSitter, is a fully automated closed‑loop system that links continuous glucose sensors to insulin pumps and directs insulin delivery via computerized control algorithms. The GlucoSitter has been tested in randomized, multicenter clinical trials on more than 220 patients and logged over 15,000 hours of operational use, with results published in leading journals including the New England Journal of Medicine. Additional development programs include insulin‑treatment profiling for clinics, patient decision‑support and educational apps, and automatic insulin delivery systems. The company positions future innovation around software and sophisticated algorithms to improve metabolic control and patient quality of life. Financially, DreaMed has entered a strategic commercial collaboration with Medtronic that includes product licensing and a minority investment.

Total raised

$8M

Funding rounds

3

Latest round

Equity

Latest activity

Aug 2024